Related Experiment Video
Updated: Mar 2, 2026
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical
Daniel Ermann1, Victoria Vardell1, Erin Zacholski2
1University of Utah Huntsman Cancer Institute, Hematology, Salt Lake City, UT.
Background:
Limited data exists comparing the efficacy of novel therapies containing brentuximab vedotin and/or checkpoint inhibitors to standard chemotherapy as treatment for relapsed/refractory classical Hodgkin Lymphoma.
Methods:
In this study, we evaluated outcomes of 162 patients receiving second-line therapy, of which 64% (n = 104) were in the chemotherapy cohort and 36% (n = 58) in the novel therapy cohort.
Results:
Over all responses for novel therapy and chemotherapy cohort were 76% versus 70% (P = .44), and complete response (CR) rates were 57% versus 46% (P = .40). The 2-year EFS rates were 72% versus 60% in novel therapy and chemotherapy cohort, respectively (P = .10). For patients who proceeded to autologous stem cell transplant (ASCT; n = 135), pretransplant CR predicted improved progression-free survival. In patients not proceeding to ASCT, prolonged 2-year EFS (86% vs. 33%, P < .01) was observed in those receiving novel therapy as second-line treatment.
Conclusions:
These data suggest improved outcomes in patients who receive novel agents compared to chemotherapy during second-line treatment.
Related Concept Videos
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:20Comparing the Survival Analysis of Two or More Groups
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...